Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Ulcerative Colitis
Interventions: SER-287, Placebo, Placebo Pre-Treat, Vancomycin Pre-Treat; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Impaired Hepatic Function
Interventions: eravacycline; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: CB-183,315, Placebo, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bacterial Infections
Interventions: Zyvox® / Linezolid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more

Conditions: Infection of Total Knee Joint Prosthesis
Interventions: Bactisure; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 2 more

Conditions: Clostridium Difficile Infection
Interventions: Oral Vancomycin; Drug
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
Interventions: Vancomycin-polymyxin B; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 4 Years to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Post-Op Complication, Spine Surgery, Site Infection, Surgical Site Infection, Spinal Instrumentation, Index Spinal Instrumentation, Layer-by-Layer Closure, Locoregional Flap-Based Closure
Interventions: Chlorhexidine gluconate solution, Vancomycin; Device · Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nephrolithiasis, Urinary Tract Infections
Interventions: nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more

Conditions: Osteoarthritis, Knee Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions: Static Spacer, Articulating Spacer; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Omadacycline, Vancomycin Pill, Moxifloxacin; Drug
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Soft Tissue Infections
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Gram-Positive Bacterial Infections
Interventions: Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Diabetic Foot Ulcer
Interventions: vancomycin-tobramycin-itraconazole; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Infection, Surgical Site
Interventions: Intraosseous Vancomycin Injection, Intravenous Vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 19 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Vancomycin continuous infusion, Vancomycin intermittent dosing interval; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacterial Infections
Interventions: Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 17 more

Conditions: Skin Structures and Soft Tissue Infections
Interventions: iclaprim, vancomycin; Drug
Lead sponsor: Motif Bio; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Buena Park, California • La Mesa, California • Long Beach, California + 12 more

Conditions: Clostridium Difficile Infection
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Dearborn, Michigan • Royal Oak, Michigan • Troy, Michigan

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions: tolevamer potassium-sodium (GT267-004); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 99
States / cities: Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more

Conditions: Prosthetic Joint Infection
Interventions: vancomycin hydrochloride and tobramycin sulfate; Combination Product
Lead sponsor: Osteal Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Saginaw, Michigan • Charlotte, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Shoulder Injuries
Interventions: Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Study of CB-183,315 in Participants With Clostridium Difficile Infection

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

Evaluating Bactisure Wound Lavage in Orthopedic Wounds

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

Gut Decontamination In Pediatric Allogeneic Hematopoietic

Irrisept Solution for Instrumented Spine Surgery

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection

Microbiome Effect of Omadacycline on Healthy Volunteers

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

IO vs IV Vancomycin in Tourniquetless TKA

Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

Study of Debio 1450 for Bacterial Skin Infections

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

Screening to Prophylax Against Clostridium Difficile Infection -

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation

IO Vancomycin in TSA